Keyphrases
Systemic Lupus Erythematosus
89%
Lupus
67%
Latin American
48%
Systemic Lupus Erythematosus Patient
48%
Multi-ethnic
45%
Rheumatology
43%
Remission
34%
COVID-19
32%
Damage Accrual
32%
SLE Disease Activity Index (SLEDAI)
23%
Peruvian
22%
Latin America (LATAM)
22%
Disease Activity
22%
Low Disease Activity
20%
Rheumatic Diseases
18%
Health-related Quality of Life
17%
Low Disease Activity State
16%
Confidence Interval
16%
Rheumatoid Arthritis
16%
Damage Index
15%
Age at Diagnosis
15%
Multivariable
15%
American College of Rheumatology
13%
Predictors of Remission
13%
Patient Data
13%
Lumen
13%
Systemic Lupus International Collaborating Clinics
12%
Prednisone
12%
COVID-19 Pandemic
12%
Mestizo
12%
Rheumatologists
11%
Immunosuppressive Drugs
10%
SLICC
10%
Systematic Literature Review
10%
Disease Duration
9%
Latino
9%
Pan American
9%
American League
8%
COVID-19 Outcomes
8%
Comorbidity
8%
American College of Rheumatology Criteria
8%
Epidemiology
8%
Autoimmune Disease
7%
Hazard Ratio
7%
Clinical Predictors
7%
Disease Outcome
7%
Risk Factors
7%
Severe Disease
7%
Early Rheumatoid Arthritis
7%
United States
7%
Medicine and Dentistry
Systemic Lupus Erythematosus
99%
Lupus Erythematosus
53%
Disease Activity
52%
Rheumatology
51%
COVID-19
30%
Disease
24%
Rheumatic Disease
23%
SLEDAI
17%
Inflammatory Arthritis
17%
Quality of Life
15%
Rheumatoid Arthritis
15%
Antimalarial Agent
11%
Prednisone
11%
Immunosuppressive Drug
10%
ANCA Associated Vasculitis
10%
Patient-Data
7%
Clinical Predictor
7%
Systematic Review
6%
Glucocorticoid
6%
Socioeconomic Status
6%
Clinical Feature
5%
Comorbidity
5%
Disease Duration
5%
Granulomatosis with Polyangiitis
5%
Autoimmune Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
100%
Disease Activity
56%
Disease
35%
Remission
34%
Inflammatory Arthritis
21%
Rheumatoid Arthritis
19%
Rheumatic Disease
19%
Antimalarial Agent
12%
Immunosuppressive Agent
11%
Infection
11%
Comorbidity
8%
Prednisone
8%
Disease Duration
8%
Glucocorticoid
7%
ANCA Associated Vasculitis
5%
Wegener Granulomatosis
5%
Autoimmune Disease
5%